论文部分内容阅读
据《罗氏新闻》透露:瑞士罗氏集团1998年上半年经营取得优异成绩,大大超过预期目标,销售额达到125亿瑞士法郎。与去年同期相比增长35％,销售纯利润达到25亿瑞士法郎,同比增长3％。这是由于罗氏集团成功兼并宝灵曼和特食美两大公司后,经营能力得到加强,药品和诊断两个分部的销售超过平均水平的结果。 罗氏在中国上海的投资公司1998年上半年的经营同样取得良好业绩,全公司销售额(不含增值税)达到7.26亿元人民币,与去年比较增长2.3％,其中药品部的销售额为2.1亿元,同比增长33.2％;维生素部的销售额为3.64亿
According to Roche News, the Swiss Roche Group achieved excellent results in the first half of 1998, significantly exceeding its anticipated target of sales of 12.5 billion Swiss francs. Compared with the same period of last year, it increased by 35% and net sales profit reached 2.5 billion Swiss francs, a year-on-year increase of 3%. This was due to the fact that after the Roche Group successfully merged two major companies, namely Bao Ling Man and Special Foods, its operating capacity was strengthened, and sales of the pharmaceutical and diagnostic divisions exceeded the average. Roche’s investment company in Shanghai, China, also performed well in the first half of 1998. Its sales (excluding VAT) totaled 726 million yuan, an increase of 2.3% compared to last year, of which pharmaceuticals sales were 210 million. Yuan, a year-on-year increase of 33.2%; vitamins sales are 364 million